Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4350860 | Neuroscience Letters | 2006 | 4 Pages |
Abstract
In the previous study of the rat frontal cortex slices oxygen consumption (QO2), polarographically determined using the biological oxygen monitor, a moderate respiratory depressant action of midazolam ex vivo (1.0 mg/kg) has been observed. Antagonist of the benzodiazepine binding site, flumazenil, blocked the effect of the agonist. However, midazolam-γ-aminobutyric acid (GABA) interactions pointed to the possibility that a part of midazolam action is independent of the classical GABA potentiation. To test this presumption, GABAA receptor antagonists bicuculline and picrotoxin were administered. Both blockers antagonized the QO2 reducing effect of the combination of per se effective doses of midazolam (1.0 mg/kg) and GABA (5 Ã 10â4 mol/l), as well as of GABA (5 Ã 10â4 mol/l) itself. However, neither effects of midazolam (1.0 mg/kg) on its own, nor those of midazolam in presence of the physiological, per se ineffective, concentration of GABA (10â6 mol/l), were susceptible to antagonism. These results show that ex vivo influence of midazolam on cerebral metabolic activity should be partly ascribed to some of its cellular mechanisms probably associated to the GABA modulation, but distinct from the standard GABA-potentiating effects of benzodiazepines.
Related Topics
Life Sciences
Neuroscience
Neuroscience (General)
Authors
Dragan I. ObradoviÄ, Miroslav M. SaviÄ, Miljana M. ObradoviÄ, Nenad D. UgreÅ¡iÄ, Dubravko R. BokonjiÄ,